1. Home
  2. ALDX vs CVEO Comparison

ALDX vs CVEO Comparison

Compare ALDX & CVEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALDX
  • CVEO
  • Stock Information
  • Founded
  • ALDX 2004
  • CVEO 1977
  • Country
  • ALDX United States
  • CVEO United States
  • Employees
  • ALDX N/A
  • CVEO N/A
  • Industry
  • ALDX Biotechnology: Pharmaceutical Preparations
  • CVEO Hotels/Resorts
  • Sector
  • ALDX Health Care
  • CVEO Consumer Discretionary
  • Exchange
  • ALDX Nasdaq
  • CVEO Nasdaq
  • Market Cap
  • ALDX 270.7M
  • CVEO 323.4M
  • IPO Year
  • ALDX 2014
  • CVEO N/A
  • Fundamental
  • Price
  • ALDX $4.81
  • CVEO $23.80
  • Analyst Decision
  • ALDX Strong Buy
  • CVEO Strong Buy
  • Analyst Count
  • ALDX 2
  • CVEO 1
  • Target Price
  • ALDX $9.50
  • CVEO $27.00
  • AVG Volume (30 Days)
  • ALDX 1.2M
  • CVEO 63.3K
  • Earning Date
  • ALDX 08-12-2025
  • CVEO 07-29-2025
  • Dividend Yield
  • ALDX N/A
  • CVEO 3.00%
  • EPS Growth
  • ALDX N/A
  • CVEO N/A
  • EPS
  • ALDX N/A
  • CVEO N/A
  • Revenue
  • ALDX N/A
  • CVEO $634,027,000.00
  • Revenue This Year
  • ALDX N/A
  • CVEO N/A
  • Revenue Next Year
  • ALDX $29.89
  • CVEO $3.64
  • P/E Ratio
  • ALDX N/A
  • CVEO N/A
  • Revenue Growth
  • ALDX N/A
  • CVEO N/A
  • 52 Week Low
  • ALDX $1.14
  • CVEO $18.01
  • 52 Week High
  • ALDX $7.20
  • CVEO $28.92
  • Technical
  • Relative Strength Index (RSI)
  • ALDX 53.97
  • CVEO 49.78
  • Support Level
  • ALDX $5.21
  • CVEO $23.38
  • Resistance Level
  • ALDX $5.35
  • CVEO $25.02
  • Average True Range (ATR)
  • ALDX 0.33
  • CVEO 0.66
  • MACD
  • ALDX -0.12
  • CVEO -0.10
  • Stochastic Oscillator
  • ALDX 40.70
  • CVEO 25.84

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

About CVEO Civeo Corporation (Canada)

Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia and the United States. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, Australia and the United States.

Share on Social Networks: